<DOC>
	<DOCNO>NCT00971841</DOCNO>
	<brief_summary>The purpose study provide access paclitaxel therapy subject advance recurrent esophageal cancer complete previous Phase 2 study ( CA139-540 ) continue therapy paclitaxel assess treat investigator ( ) . To evaluate severity observed adverse reaction treat subject assessment long-term safety .</brief_summary>
	<brief_title>Rollover Study Weekly Paclitaxel ( BMS-181339 ) Patients With Advanced Recurrent Esophageal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Subjects advance recurrent esophageal cancer complete previous late Phase 2 study ( CA139540 ) continue therapy paclitaxel would beneficial deem investigator ( ) .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>